Strategic partnerships Avectas is actively collaborating with industry players like CCRM and OmniaBio to evaluate and scale its automated, integrated cell therapy manufacturing platform, representing a direct opening for sales teams to position Solupore as a scalable GMP-friendly solution for contract manufacturing and technology licensing.

Growth potential With a recent funding environment and revenue trajectory in the low to mid seven figures, Avectas is positioned to expand its Solupore platform adoption across cell therapies, offering a compelling opportunity to upsell broader platform integration and ongoing support services to accelerate market readiness.

Non-viral edge Solupore’s non-viral delivery approach emphasizes high cell health and functionality, which can be marketed to sponsors seeking safer, scalable gene editing and delivery workflows, creating a strong value proposition for collaboration on next‑generation cell therapies.

GMP integration Easy integration into existing GMP processes is a key differentiator, suggesting immediate sales targets in biopharma CDMOs and biotech groups looking to enhance manufacturing efficiency without overhauling their current manufacturing stack.

Market proof Active media coverage of Avectas partnerships and leadership changes indicates growing market recognition and validation, enabling sales to leverage brand momentum when approaching potential customers and strategic investors.